A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

por Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M
Publicado 2011

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS

por Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Jacobsen, E. D., Gritti, G., Pinter-Brown, L., Isutzu, K., Cohan, D., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., Horwitz, S. M.
Publicado 2022